CoChat

Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis.

Callahan, M. K., Yang, A., Tandon, S., Xu, Y., Subudhi, S. K., Roman, R. A., Heine, A. I., Pogoriler, E., Kuk, D., Panageas, K., Yuan, J. D., Allison, J. P., Wolchok, J. D. · 2011 · Journal of Clinical Oncology
Cited by 129

The DOI matches its Crossref record.

Abstract

2505 Background: Ipilimumab is the first agent to demonstrate a survival benefit in patients with metastatic melanoma in a randomized phase III clinical trial. Immune-related adverse events (irAEs) are the most common side effects associated with ipilimumab. Grade III/IV irAEs occur in approximately 10-15% of patients, and colitis is the most common irAE within this group. Ipilimumab-associated colitis has been managed effectively with immunosuppressive medications in clinical trials. IL-17 is an important mediator of autoimmunity and inflammation that has been implicated in colitis. We evaluated serum IL-17 levels in patients treated with ipilimumab, comparing patients who developed colitis to those without irAEs. Methods: Patients with metastatic melanoma received 10 mg/kg of ipilimumab on an expanded access protocol (EAP) (CA184-045). We obtained serum samples from 52 serially accrued EAP patients. Samples were collected pre-treatment and at appointed intervals during treatment. The serum concentration of IL-17 at each time point was quantitated using the Meso Scale Discovery system. Patients were classified into three groups based upon clinical symptoms: (1) colitis, (2) no irAE, or (3) non-colitis irAE. Results: Pairwise comparison of serum IL-17 levels in patients with colitis (n=13) versus no irAEs (n=16) demonstrated significantly higher serum IL-17 levels in patients with colitis at week 7 (p=0.007) and week 12 (p=0.02). In individual patients, development and resolution of colitis symptoms temporally correlated with increases and decreases in serum IL-17, respectively. Upon resolution of clinical symptoms, IL-17 levels in patients with colitis decreased to levels comparable to patients without colitis. Pre-treatment IL-17 levels were not significantly different between patients with or without colitis or between patients and healthy donor controls. This pattern was unique when compared with several additional cytokines tested. Conclusions: We report that the development and resolution of colitis is significantly associated with fluctuations in serum IL-17 in this subset of ipilimumab-treated patients, reinforcing the immune-based mechanism of the most common ipilimumab side effect.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.29.15_suppl.2505

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 129

Metadata

Authors
Callahan, M. K., Yang, A., Tandon, S., Xu, Y., Subudhi, S. K., Roman, R. A., Heine, A. I., Pogoriler, E., Kuk, D., Panageas, K., Yuan, J. D., Allison, J. P., & Wolchok, J. D.
Venue
Journal of Clinical Oncology
Published
2011-05-20
Volume
29
Issue
15_suppl
Pages
2505-2505
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2591431100
Cited by
129
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. https://app.cochat.ai/papers/10.1200/jco.2011.29.15_suppl.2505
The paper
Callahan, M. K., Yang, A., Tandon, S., Xu, Y., Subudhi, S. K., Roman, R. A., Heine, A. I., Pogoriler, E., Kuk, D., Panageas, K., Yuan, J. D., Allison, J. P., & Wolchok, J. D. (2011). Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.29.15_suppl.2505

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.